Sold as Reno-Dip, RENO-60, Diatrizoate Meglumine, Cystografin, RENO-30 and 4 more. Every FDA application for this active ingredient: 3 branded and 4 generic.
As of Nov 22, 2026, FDA lists 7 applications for Diatrizoate meglumine (sold as Reno-Dip, RENO-60, Diatrizoate Meglumine and others), first approved Aug 2, 1955, with 5 new uses approved and 0 published complete response letters.
| Aug 2, 1955 | Renografin-76, Renografin-60NDA 10040 ยท New active ingredient, new combination | Bracco Imaging | 95 | Marketed |
| Dec 3, 1958 | CardiografinNDA 11620 ยท New formulation or manufacturer | Bracco Imaging | 13 | Discontinued |
| Aug 21, 1969 | Hypaque, Hypaque-CystoNDA 16403 ยท New dosage form | GE Healthcare | 59 | Discontinued |
| Sep 23, 1982 | Angiovist 282ANDA 87726 | Bayer Healthcare | 1 | Discontinued |
| Sep 23, 1982 | Urovist CystoANDA 87729 | Bayer Healthcare | 1 | Discontinued |
| Sep 23, 1982 | Urovist Cysto PediatricANDA 87731 | Bayer Healthcare | 1 | Discontinued |
| Sep 23, 1982 | Urovist Meglumine Diu/CtANDA 87739 | Bayer Healthcare | 0 | Discontinued |
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Gastrografin | Part B | $7K | +2% | 901 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| Optimizing Treatment of Adhesive Small Bowel ObstructionAdhesive Small Bowel Obstruction ยท University of California, Los Angeles | Phase 3 | Recruiting | Dec 26, 2023 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered. Drugs@FDA